Koc Namli Sule, Ayd�±n Muhammed Fatih, Akarsu Mesut, Unek Tarkan, Sagol Ozgul and Akp�±nar Hale
Alt�±nbas University, Istanbul
Dokuz eyl�¼l University, Turkey
Posters & Accepted Abstracts: J Clin Gastroenterol Hepatol
Background & Aim: The objective is to evalaute the relation between gastro-entero-pancreatic neuroendocrine tumors (GEP-NET) and glucagon like peptide-2 (GLP-2) & GLP-2 R. Material and Methods: The patients, who were pathologically diagnosed with GEP-NET between 2006 and 2009, were included in the study. There were 47 patients (27 F, 20 M, average age: 54±15.5) in the study. There were also 46 control group patients (25 F, 21 M, average age: 57.5±14.8). Pathological tissue blocks prepared on poly-L-lysine microscope slides were stained by GLP-2 Receptor Antibody (1:100-1:200, 1 mg/ml) immunohistochemical stain Results: GLP-2R positivity of colon neuroendocrine tumour (NET) group was 30 % (4/13)) and of colon control group was 100%. GLP2R positivity of pancreas NET group was 25% (3/12) while it was 100 % in pancreas control group. The comparison of colon NET and control group showed significant difference (p: 0.003). The comparison of pancreas NET and control group also showed statistically significant difference (p<0.001). The comparison of gastric NET with the control yielded comparable results (p: 0.22). Conclusion: Neuroendocrine tumours (NETs) consist of a heterogeneous group of malignancies with slow growth rates and they are rare tumours. Although there is a hypothesis that carcinoid tumours arising from intestinal endocrine cells might also exhibit GLP-2R immunopositivity, and it can be used in diagnosis and treatment of these tumours; this study didn’t show an obvious GLP2 R expression in GEP-NET’s. We concluded that GLP2R cannot be as useful as somatostatin receptors in diagnosis and treatment of these tumours. More studies are needed on this subject with different methods
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 